Yuki Gosei Kogyo (4531) · RiskMaterialised
Delays in Approvals for New Pharmaceutical Facilities and Depreciation Expense Burden
First written in FY2018. 1 of 2 entries say "Materialised", first in FY2019. Latest entry: FY2019.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Delayed Start-Up and Depreciation Burden from Permitting Delays for New Pharmaceutical FacilitiesA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2019MaterialisedAnnual report
「The new pharmaceutical facility completed last year has required more time than initially anticipated for permit procedures with the relevant authorities, and it will take some more time before full-scale operations begin.」
The company states that permit procedures for the new pharmaceutical facility have taken longer than anticipated, resulting in an actual delay to the start of full-scale operations. - FY2018First statedAnnual report
「The newly completed pharmaceutical facility will require more time than initially anticipated for permit procedures with the relevant authorities, and will also incur depreciation expense.」
The company states that although the new pharmaceutical facility has been completed, permit procedures have taken longer than initially anticipated, resulting in depreciation expense being incurred before operations begin.